SCHEMBL17052736

SCHEMBL17052736

CNC(=O)c1ccccc1SCCCCCC(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 6/20 0.48
▸ POLB P06746 3/20 0.48
▸ ALDH1A1 P00352 7/20 0.46
▸ HPGD P15428 3/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ ALOX15 P16050 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ PTGS2 P35354 3/20 0.45
▸ TDP1 Q9NUW8 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18922452 0.86 PTGS2 (0.47) HSD17B10POLBALDH1A1HPGDALOX12
SCHEMBL17045909 0.86 HSD17B10 (0.65) HSD17B10POLBALDH1A1ALOX15PKM
SCHEMBL26445665 0.86 PTGS2 (0.50) HSD17B10POLBALDH1A1PTGS2LMNA
SCHEMBL17052733 0.86 PTGS2 (0.50) HSD17B10POLBALDH1A1HPGDALOX15
SCHEMBL7471148 0.81 HSD17B10 (0.68) HSD17B10POLBALDH1A1HPGDALOX15
SCHEMBL17045927 0.81 EPHX2 (0.52) HSD17B10POLBALDH1A1PTGS2LMNA
SCHEMBL20545021 0.80 PTGS2 (0.48) HSD17B10POLBALDH1A1PTGS2LMNA
SCHEMBL20545058 0.80 MTNR1A (0.58) POLBALDH1A1PTGS2
SCHEMBL20545177 0.80 PTGS2 (0.48) HSD17B10POLBALDH1A1PTGS2LMNA
SCHEMBL31734065 0.78 MEN1 (0.53) TDP1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10233201-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburg—Of the Commonwealth System of Higher Education (US) 2019-03-19 — — US disclosed
US-10233201-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburg—Of the Commonwealth System of Higher Education (US) 2019-03-19 — — US disclosed
US-20170320898-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2017-11-09 — — US disclosed
US-20170320898-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2017-11-09 — — US disclosed
US-20170320898-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2017-11-09 — — US disclosed
US-9670236-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-06-06 — — US disclosed
US-9670236-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-06-06 — — US disclosed
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2015-09-03 — — US disclosed
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2015-09-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233201-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 HSD17B10 664/4885POLB 1451/4885ALDH1A1 351/4885
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 HSD17B10 664/4885POLB 1451/4885ALDH1A1 351/4885
US-20170320898-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 HSD17B10 664/4885POLB 1451/4885ALDH1A1 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback